TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01833858

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients received rFSH injections with Placebo starting on cycle day 3 of the stimulation cycle until the day of hCG trigger administration.
Study: NCT00295282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDX-1100 (anti-CXCL10 human monoclonal antibody)
Description: Patients will receive a single dose of MDX-1100 at 0.3, 1.0, 3.0 or 10 mg/kg as a 60 minute intravenous infusion. Patients who respond to treatment may receive up to an additional 3 doses of MDX-1100.
Study: NCT01397045

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VATS
Description: Video-assisted lung segmentectomy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mini thoracotomy
Description: Mini muscle sparing thoracotomy for lung segmentectomy
Study: NCT01117025

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Circumferential PV isolation
Description: The left atrium (LA) and pulmonary veins (PVs) are explored through a transeptal approach. Real-time 3D LA maps are reconstructed by using a nonfluoroscopic navigation system. The ipsilateral left and right PVs are encircled in one lesion line by circumferential PV isolation. Radiofrequency energy is delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and is reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion is ablated continuously until the local potential amplitude decreased by \>80% or RF energy deliveries exceeded 40 s. The endpoint of circumferential PV isolation is PV isolation. Additional ablation lines are created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the roof of the LA between the two superior PVs. After the end of the procedure the implantable loop recorder is implanted in the parasternal area of the chest.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Circumferential PVI+renal denervation
Description: The procedure of AF ablation is the same like in the circumferential PV isolation.~After AF ablation procedure, the angiogram of both renal arteries is performed via femoral access. After that the treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done.
Study: NCT02391974

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PERIOSYAL FILL
Description: Injection 2 weeks after standard periodontal treatment procedure on all teeth that need to be treated.~Touch-up treatment provided at 3 and 6 weeks.
Study: NCT00457756

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: BiosLife Complete
Study: NCT00106340

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vildagliptin matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride matching placebo
Study: NCT00634881

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alemtuzumab i.v.
Description: Alemtuzumab will be administered once per week as a 2 h infusion~* Dose level I: 10mg once weekly (start with dose escalation : 3 mg on day 1, 10mg on day 2) Duration~* Dose level II: 20mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 20mg on day 3)~* Dose level III: 30mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 30mg on day 3)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alemtuzumab s.c.
Description: Alemtuzumab will be administered once per week subcutaneously~* Dose level I: 10mg once weekly (start with dose escalation : 3 mg on day 1, 10mg on day 2) Duration~* Dose level II: 20mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 20mg on day 3)~* Dose level III: 30mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 30mg on day 3)
Study: NCT01930955

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: β-lactam antibiotics
Study: NCT03810014

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conditional ACT subsidy, Arm 1 levels
Description: The subsidy levels for participants randomly assigned to Arm 1 are: No subsidy for RDT (price to consumer=$0.40); 100% ACT subsidy (price to consumer=0).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conditional ACT subsidy, Arm 2 levels
Description: The subsidy levels for participants randomly assigned to Arm 2 are: No subsidy for RDT (price to consumer=$0.40); 67% ACT subsidy (price to consumer=$0.10-0.40, dependent upon patient age).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conditional ACT subsidy, Arm 3 levels
Description: The subsidy levels for participants randomly assigned to Arm 3 are: 50% subsidy for RDT (price to consumer=$0.20); 100% ACT subsidy (price to consumer=0).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conditional ACT subsidy, Arm 4 levels
Description: The subsidy levels for participants randomly assigned to Arm 4 are: 50% subsidy for RDT (price to consumer=$0.20); 67% ACT subsidy (price to consumer=$0.10-0.40, dependent upon patient age)
Study: NCT01212354

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 7 weeks Radiation dose escalation (5 x 2.3 Gy up to 80.5 Gy total dose)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: 7 weeks Radiation dose escalation (5 x 2.3 Gy up to 80.5 Gy total dose)
Study: NCT02528513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: Midazolam is started with an infusion bolus of 0.03-0.30 mg/kg and continuous infusion of 0.03-0.20 mg/kg/h, with the dosage adjusted to RASS score (-3 to 0).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: Midazolam is started with an infusion bolus of 0.03-0.30 mg/kg and continuous infusion of 0.03-0.20 mg/kg/h, with the dosage adjusted to RASS score (-3 to 0).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: Midazolam is started with an infusion bolus of 0.03-0.30 mg/kg and continuous infusion of 0.03-0.20 mg/kg/h, with the dosage adjusted to RASS score (-3 to 0).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl is used with bolus dosage of 1-2ug/kg and maintenance dosage of 1-2ug/kg/h, with the dosage adjusted to critical care pain observation tool（CPOT）score(0-1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl is used with bolus dosage of 1-2ug/kg and maintenance dosage of 1-2ug/kg/h, with the dosage adjusted to critical care pain observation tool（CPOT）score(0-1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl is used with bolus dosage of 1-2ug/kg and maintenance dosage of 1-2ug/kg/h, with the dosage adjusted to critical care pain observation tool（CPOT）score(0-1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: After the spontaneous breathing trial safety screen is passed, midazolam is switched to propofol, which is administered at the maintenance dosage of 0.50-3.00mg/kg/h, with the dosage adjusted to RASS score (-2 to 0).
Study: NCT01151020

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zenith® TX2® Low Profile TAA Endovascular Graft
Description: Endovascular treatment of patients with aneurysms/ulcers of the descending thoracic aorta having morphology suitable for endovascular repair
Study: NCT00610259

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: brief behavioral therapy for insomnia (bBT-I)
Description: 4 50-minute individual sessions every week for 4 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual (TAU)
Description: The psychiatrist-in-charge sees the patient once every 2 weeks for approximately 10 minutes each to monitor pharmacotherapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: The psychiatrist-in-charge sees the patient once every 2 weeks for approximately 10 minutes each to monitor pharmacotherapy.
Study: NCT01925768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg
Description: 30mg of Apremilast will be orally administered twice daily for 104 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identically appearing Placebo tablets will be orally administered twice daily for up to 24 weeks
Study: NCT02372695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Study: NCT01962428

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ticagrelor
Description: Patients will receive ticagrelor 360mg loading dose or 180mg loading dose , then 90mg bid maintenance dose starting 12 hours after loading dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Description: Patients will receive ticagrelor 360mg loading dose or 180mg loading dose , then 90mg bid maintenance dose starting 12 hours after loading dose.
Study: NCT03235193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Severe Sepsis Prediction
Description: Upon receiving an InSight alert, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Severe Sepsis Detection
Description: Upon receiving information from the severe sepsis detector in the CHH electronic health record, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Severe Sepsis Detection
Description: Upon receiving information from the severe sepsis detector in the CHH electronic health record, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
Study: NCT04760483

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SoracteLite(TM) TPLA for BPH
Description: see prior section
Study: NCT02819297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI400 Laxative
Description: 21 gm BLI400 powder
Study: NCT03268369

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET scan [18F]FDG
Description: exam performed after iv injection of 200 MBq \[18F\]FDG
Study: NCT02819297

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BLI400 Placebo
Description: Equivalent amount of placebo powder
Study: NCT02069977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Study: NCT00260728

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vascular access graft implantation
Description: vascular access graft implantation
Study: NCT02487758

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ridge Preservation
Description: Ridge Preservation Comparing the Clinical and Histologic Healing of Flap vs. Flapless Approach to Grafting
Study: NCT02528513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: After the spontaneous breathing trial safety screen is passed, midazolam is switched to dexmedetomidine, which is administered at an infusion bolus of 0.5μg/kg over 10 min (given or not according to patients' condition) and the maintenance dosage of 0.2-0.7ug/kg/h, with the dosage adjusted to RASS score (-2 to 0).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procedure:sedation assessment
Description: The nursing staff continuously monitored the sedation depth and adjusted the dosages of sedative and analgesic drugs to maintain the sedation target level. The sedation depth were assessed and recorded every 4 h (or more frequently when indicated).
Study: NCT00530634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study: NCT03207854

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of peripheral blood, bone marrow, and tissue

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00530634

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT04023383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 cc HyaRegen NCH gel
Description: After an extensive bleeding control the patients in the intervention group had 40 mL of HyaRegen NCH gel instilled into the peritoneal cavity.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 40 cc sterile saline solution
Description: After an extensive bleeding control the patients in the control group had 40 cc sterile saline solution compatible with the body temperature.
Study: NCT01364129

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ophthalmic Telemedicine
Description: Participants receiving the intervention have digital images of their retina captured with a non-mydriatic camera. The images are then sent to Devers Eye Institute for review and report generation.
Study: NCT00457756

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01175590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Besivance
Description: Ocular administration to affected eye for 7 days
Study: NCT00755963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estradiol valerate
Description: Progynova® 21; 2mg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estradiol valerate
Description: Progynova® 21; 2mg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: micronized progesterone
Description: Utrogestan®; 200mg/d
Study: NCT05430932

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy
Description: Laparoscopic resection of a part of the stomach to enable the patient to lose weight.
Study: NCT00923156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aliskiren
Description: Aliskiren 150 mg once daily up titrated to 300 mg once daily after 1 week of treatment following a clinical safety patient assessment at the study site

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aliskiren
Description: Aliskiren 150 mg once daily up titrated to 300 mg once daily after 1 week of treatment following a clinical safety patient assessment at the study site

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramipril
Description: 2.5 mg , 5.0 mg or 10 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramipril
Description: 2.5 mg , 5.0 mg or 10 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramipril
Description: 2.5 mg , 5.0 mg or 10 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to aliskiren
Description: matching placebo to aliskiren in double blind phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to ramipril
Description: Matching placebo to ramipril capsule in double blind phase
Study: NCT01954719

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cervix dilated after surgery
Description: The surgeon inserted his or her double-gloved index digit in the cervical canal to dilate it and removed the outer gloves after digital dilatation of the cervix.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: control group
Description: surgeon not dilated cervix after surgery
Study: NCT04490850

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood sample
Study: NCT05476471

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multicomponent exercise training program
Description: One supervised 60 minutes training sessions per week were organized combining warm-up, speed-walking, resistance exercise, static and dynamic balance. Supervised walking sessions were for 10-20 minutes at a target intensity of 13-15 on the Borg scale. Thereafter, 10 resistance exercises targeting lower body, trunk and upper body muscles were performed with elastic band. In addition, participants were instructed to accumulate 150 minutes per week of moderate intensity aerobic activity in bouts of at least 10 minutes, and at least 2-3 days all major muscle groups training.
Study: NCT00749645

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FANG(30)
Description: Andrographolide formula Oral tablets, 30mg, three times per day, during a total of 105 continuous days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 30mg tabs, 3/day, 105 days continuously.
Study: NCT03675100

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: colonoscopic mucosal biopsy
Description: colonoscopic mucosal biopsy was undertaken for every participant

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: colonoscopic mucosal biopsy
Description: colonoscopic mucosal biopsy was undertaken for every participant
Study: NCT02528513

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procedure:sedation assessment
Description: The nursing staff continuously monitored the sedation depth and adjusted the dosages of sedative and analgesic drugs to maintain the sedation target level. The sedation depth were assessed and recorded every 4 h (or more frequently when indicated).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procedure:sedation assessment
Description: The nursing staff continuously monitored the sedation depth and adjusted the dosages of sedative and analgesic drugs to maintain the sedation target level. The sedation depth were assessed and recorded every 4 h (or more frequently when indicated).
Study: NCT03214939

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunotherapy based on dendritic cells
Description: Intravenous injection of cells
Study: NCT01146418

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa
Description: Single injection of 150 μg corifollitropin alfa administered under protocol P06029

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: recFSH (follitropin beta)
Description: Daily recFSH 300 IU administered under protocol P06029.
Study: NCT03845985

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Seeking Safety + Signs of Safety toolkit
Description: Seeking Safety is an existing, present-focused, first-stage manualized treatment for trauma and addiction. Session content engages clients in themes relevant to addiction and trauma, and to help them learn a specific skill to target symptoms of both AUD and PTSD (e.g., Coping with Triggers, Asking for Help).~Signs of Safety is a culturally and linguistically Deaf-accessible toolkit to be used alongside Seeking Safety. The toolkit includes a therapist guide and population-specific client materials (e.g., visual handouts; ASL teaching stories on digital video). It is designed for Deaf/signing clinicians, as well as non-signing clinicians working with ASL interpreters.
Study: NCT02004119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4577

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04667871

Intervention type: PROCEDURE
Intervention: cataract surgery
Description: Eyes for cataract surgery
Study: NCT02528513

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procedure:Weaning
Description: the respiratory therapists managed patients with a daily interruption of continuous sedation and the spontaneous breathing trial (SBT) protocols daily.
Study: NCT04154384

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Coordination with Referrals
Description: The Life Care Specialist (LCS) can help arrange a referral for the participant, should a medical or social issue be identified during LCS intervention, including mental health services, addiction medicine services, housing insecurity referrals, food insecurity referrals, and amputee support. When giving referrals, the LCS works closely with physicians and nurses to make sure that the participant is a good fit for the referral program.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pilot Study of Pain Management Strategies
Description: Orthopedic trauma patients will work with a Life Care Specialist (LCS) and will receive personalized pain management strategies to avoid potential opioid misuse.
Study: NCT01136876

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iopamidol
Description: Iopamidol 370, one time administration for percutaneous coronary intervention
Study: NCT02528513

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procedure:Weaning
Description: the respiratory therapists managed patients with a daily interruption of continuous sedation and the spontaneous breathing trial (SBT) protocols daily.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procedure:Weaning
Description: the respiratory therapists managed patients with a daily interruption of continuous sedation and the spontaneous breathing trial (SBT) protocols daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam(used for passing the SBT safety screen)
Description: After the spontaneous breathing trial safety screen is passed,in the midazolam group, midazolam will continue to be used for sedation, with the dosage adjusted to RASS score (-2 to 0).
Study: NCT02951442

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological sample

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non invasive Arterial investigations

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal tomodensitometry
Study: NCT01440036

Intervention type: PROCEDURE
Intervention: Carotid endarterectomy
Description: The removal of atherosclerotic plaque from the carotid artery, by surgery
Study: NCT03653117

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transperineal laser ablation
Description: Minimal invasive coagulation of prostatic tissue by laser
Study: NCT02854111

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ice cream
Description: The ice cream was made by nutritionists in Ramathibodi Hospital. It consisted of cornstarch, milk, sucrose, milk powder, egg yolk, and banana which contained carbohydrate 73.9 g, fat 27.7 g, protein 18.9 g for a total of 620.9 kcal with a cost of 35 bahts. The time for complete ingesting 75-g glucose and ice cream was 5 and 15 minutes, respectively.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 75 g-glucose
Description: The 75-g glucose is used for standard oral glucose tolerance test.